Incretin Atlas › Trials › UBT251 phase 2 T2D China (NCT07163624)
UBT251 phase 2 T2D China (NCT07163624)
UBT251 · t2d
Design
- Molecule(s)
- UBT251
- Population
- t2d
- Phase
- 2
- Participants
- 211
- Duration
- 24 weeks
- Registry
- NCT07163624
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.0 mg (initial dose 0.5 mg) vs semaglutide 1 mg: weight -4.8 %, HbA1c -1.77 | t2d china | 24 | 211 | — | — | −2.0 vs −0.7 | — | — | — | — | — | — | congress |
| 4.0 mg (initial dose 1.0 mg) vs semaglutide 1 mg: weight -4.8 %, HbA1c -1.77 | t2d china | 24 | 211 | — | — | −2.1 vs −0.7 | — | — | — | — | — | — | congress |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- 4.0 mg (initial dose 0.5 mg): Published in Cell Metabolism (26 October 2026, PMID 42933400): the abstract gives the HbA1c range across UBT251 arms (−2.16 to −1.98), semaglutide 1 mg −1.77 and placebo −0.66; per-arm weight and safety await the full text.
- 4.0 mg (initial dose 1.0 mg): Published in Cell Metabolism (26 October 2026, PMID 42933400): the abstract gives the HbA1c range across UBT251 arms (−2.16 to −1.98), semaglutide 1 mg −1.77 and placebo −0.66; per-arm weight and safety await the full text.
Verbatim quotes from the source (2)
- 4.0 mg (initial dose 0.5 mg) · hba1c · abstract
change in HbA1c was -2.16% (0.122), -1.98% (0.169), -2.08% (0.170) and -2.08% (0.118) with
- 4.0 mg (initial dose 1.0 mg) · hba1c · abstract
change in HbA1c was -2.16% (0.122), -1.98% (0.169), -2.08% (0.170) and -2.08% (0.118) with
Primary sources
- Zhou Z, Shi X, Jiang S, Wang S, Shu H, Sun W, et al. UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with type 2 diabetes: A multicenter, randomized phase 2 trial. Cell Metab. 2026. PMID: 42933400.
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd64052.
How to cite this page
Medical Adviser's Group. Incretin Atlas: UBT251 phase 2 T2D China (NCT07163624). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-t2d-china/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.